Home Stocks PYC Therapeutics Limited OTC:PYCXF Stock listing
OTC:PYCXF PYC Therapeutics Limited Stock US listing (OTC) of PYC Therapeutics Limited · home listing ASX:PYC
Follow PYC Therapeutics Limited into a list and get an email when it puts out news.
Share price · OTC:PYCXF
$1.22 USD -0.03 (-2.5%)
Close on Nov 13, 2026
Past year +47.7% · daily closes, Nov 13, 2025 – Nov 6, 2026, adjusted for splits
Day range $1.22 – $1.22 USD Nov 13, 2026
Volume 900 shares Nov 13, 2026
Market cap $1.23B USD At the close on Nov 13, 2026 · price × 1.01B shares outstanding
52-week range $0.846 – $1.80 USD Lowest and highest trades, Nov 14, 2025 – Nov 13, 2026
Traded on an average day $1,143 USD Median day 0 shares · 53 days with no trades · last 3 months, Aug 13, 2026 – Nov 6, 2026 Prices by listing Listing Last Change Volume Open High Low Previous close Price from ASX:PYC · Home $1.645 AUD -0.09 (-5.2%) 5,097,493 $1.625 $1.673 $1.598 $1.735 Close on Nov 20, 2026 OTC:PYCXF $1.219 USD -0.031 (-2.5%) 900 $1.219 $1.219 $1.219 $1.25 Close on Nov 13, 2026
Daily closes Last 3 months, Aug 13, 2026 – Nov 6, 2026 · OTC:PYCXF · USD, adjusted for splits
Day Close Change % Open High Low Volume Fri, Nov 6 $1.25 0.00 0.0% $1.25 $1.25 $1.25 0 Thu, Nov 5 $1.25 0.00 0.0% $1.25 $1.25 $1.25 0 Wed, Nov 4 $1.25 0.00 0.0% $1.25 $1.25 $1.25 0 Tue, Nov 3 $1.25 0.00 0.0% $1.25 $1.25 $1.25 0 Mon, Nov 2 $1.25 0.00 0.0% $1.25 $1.25 $1.25 0 Fri, Oct 30 $1.25 0.00 0.0% $1.25 $1.25 $1.25 0 Thu, Oct 29 $1.25 0.00 0.0% $1.25 $1.25 $1.25 0 Wed, Oct 28 $1.25 0.00 0.0% $1.25 $1.25 $1.25 0 Tue, Oct 27 $1.25 0.00 0.0% $1.25 $1.25 $1.25 0 Mon, Oct 26 $1.25 -0.015 -1.2% $1.25 $1.25 $1.25 4,400 Fri, Oct 23 $1.265 0.00 0.0% $1.265 $1.265 $1.265 0 Thu, Oct 22 $1.265 +0.005 +0.4% $1.265 $1.265 $1.265 3,300 Wed, Oct 21 $1.26 0.00 0.0% $1.26 $1.26 $1.26 0 Tue, Oct 20 $1.26 -0.22 -14.9% $1.26 $1.26 $1.26 12,720 Mon, Oct 19 $1.48 0.00 0.0% $1.48 $1.48 $1.48 0 Fri, Oct 16 $1.48 0.00 0.0% $1.48 $1.48 $1.48 0 Thu, Oct 15 $1.48 0.00 0.0% $1.48 $1.48 $1.48 0 Wed, Oct 14 $1.48 -0.27 -15.4% $1.48 $1.48 $1.48 5,050 Tue, Oct 13 $1.75 0.00 0.0% $1.75 $1.75 $1.75 0 Mon, Oct 12 $1.75 0.00 0.0% $1.75 $1.75 $1.75 0 Fri, Oct 9 $1.75 0.00 0.0% $1.75 $1.75 $1.75 0 Thu, Oct 8 $1.75 0.00 0.0% $1.75 $1.75 $1.75 0 Wed, Oct 7 $1.75 0.00 0.0% $1.75 $1.75 $1.75 0 Tue, Oct 6 $1.75 0.00 0.0% $1.75 $1.75 $1.75 0 Mon, Oct 5 $1.75 0.00 0.0% $1.75 $1.75 $1.75 0 Fri, Oct 2 $1.75 0.00 0.0% $1.75 $1.75 $1.75 0 Thu, Oct 1 $1.75 0.00 0.0% $1.75 $1.75 $1.75 0 Wed, Sep 30 $1.75 0.00 0.0% $1.75 $1.75 $1.75 0 Tue, Sep 29 $1.75 0.00 0.0% $1.75 $1.75 $1.75 0 Mon, Sep 28 $1.75 0.00 0.0% $1.75 $1.75 $1.75 0 Fri, Sep 25 $1.75 0.00 0.0% $1.75 $1.75 $1.75 0 Thu, Sep 24 $1.75 0.00 0.0% $1.75 $1.75 $1.75 0 Wed, Sep 23 $1.75 0.00 0.0% $1.75 $1.75 $1.75 0 Tue, Sep 22 $1.75 0.00 0.0% $1.75 $1.75 $1.75 0 Mon, Sep 21 $1.75 0.00 0.0% $1.75 $1.75 $1.75 0 Fri, Sep 18 $1.75 0.00 0.0% $1.75 $1.75 $1.75 0 Thu, Sep 17 $1.75 0.00 0.0% $1.75 $1.75 $1.75 0 Wed, Sep 16 $1.75 0.00 0.0% $1.75 $1.75 $1.75 0 Tue, Sep 15 $1.75 0.00 0.0% $1.75 $1.75 $1.75 0 Mon, Sep 14 $1.75 0.00 0.0% $1.75 $1.75 $1.75 0 Fri, Sep 11 $1.75 0.00 0.0% $1.75 $1.75 $1.75 0 Thu, Sep 10 $1.75 0.00 0.0% $1.75 $1.75 $1.75 0 Wed, Sep 9 $1.75 -0.05 -2.8% $1.75 $1.75 $1.75 2,500 Tue, Sep 8 $1.80 0.00 0.0% $1.80 $1.80 $1.80 0 Fri, Sep 4 $1.80 +0.30 +20.0% $1.80 $1.80 $1.80 2,000 Thu, Sep 3 $1.50 0.00 0.0% $1.50 $1.50 $1.50 0 Wed, Sep 2 $1.50 0.00 0.0% $1.50 $1.50 $1.50 0 Tue, Sep 1 $1.50 0.00 0.0% $1.50 $1.50 $1.50 0 Mon, Aug 31 $1.50 0.00 0.0% $1.50 $1.50 $1.50 0 Fri, Aug 28 $1.50 0.00 0.0% $1.50 $1.50 $1.50 0 Thu, Aug 27 $1.50 0.00 0.0% $1.50 $1.50 $1.50 0 Wed, Aug 26 $1.50 0.00 0.0% $1.50 $1.50 $1.50 0 Tue, Aug 25 $1.50 0.00 0.0% $1.50 $1.50 $1.50 0 Mon, Aug 24 $1.50 0.00 0.0% $1.50 $1.50 $1.50 0 Fri, Aug 21 $1.50 0.00 0.0% $1.50 $1.50 $1.50 0 Thu, Aug 20 $1.50 0.00 0.0% $1.50 $1.50 $1.50 0 Wed, Aug 19 $1.50 0.00 0.0% $1.50 $1.50 $1.50 6,000 Tue, Aug 18 $1.50 0.00 0.0% $1.50 $1.50 $1.50 0 Mon, Aug 17 $1.50 0.00 0.0% $1.50 $1.50 $1.50 0 Fri, Aug 14 $1.50 +0.35 +30.4% $1.50 $1.50 $1.50 13,066 Thu, Aug 13 $1.15 0.00 0.0% $1.15 $1.15 $1.15 0
Ticker OTC:PYCXF
Asset type Stock
Sector Health care
Industry Biotechnology
Exchange OTC
Currency USD What changed lately Latest news release · Nov 12, 2026
Latest deck · Nov 12, 2026
Shareholder meeting · 37 slides
PYC Therapeutics Limited on 6ix
News releases 49 in the last 12 months · 284 in all · newest Nov 12, 2026 · oldest 2016
Decks 102 decks · latest Nov 12, 2026 Where PYC Therapeutics Limited is listed Listing Exchange Country Currency ASX:PYC · Home listing ASX Australia AUD OTC:PYCXF · This page OTC United States USD
On this page Valuation Price/book 2.3× against a median of 4.5×: 4th lowest of 11 Biotechnology companies shown. Statements: Year to Jun 30, 2026 · price Nov 20, 2026
Enterprise value $1.17B AUD
P/E Loss
EV/sales No revenue
EV/EBITDA Negative EBITDA
Price/book 2.3×
Gross margin No revenue
Operating margin No revenue
Net margin No revenue
Debt to equity 0.0×
Beta No index for this market yet Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
Forecasts Analysts' consensus from EODHD, read Nov 10, 2026. Not 6ix's view and not investment advice.
Price target 4.07 AUD · Analysts' mean
EPS, year to Jun 2027 -0.082 · 5 analysts Team and board Officers Officer Role Rohan Hockings Executive Director & Chief Executive Officer Thomas Ulmer Chief Financial Officer Garrett Bray Chief Operating Officer Jonathan Riley General Counsel Candice Junge Chief Clinical Development Officer Janya Grainok Chief Scientific Officer Paula Cunningham Chief Development Officer
Events Quarter Results Share move Q4 2025 Aug 27, 2025 · Before open −0.4% Q2 2025 Feb 27, 2025 +2.9% Q2 2023 Feb 28, 2023 · After close +2.6% Q4 2022 Sep 23, 2022 · Before open −3.9% Q2 2022 Feb 28, 2022 −2.9% Q4 2021 Aug 31, 2021 +3.3% Q2 2021 Feb 26, 2021 +3.6%
Open Events
Decks Deck Kind Slides Date Shareholder Meeting (November 2026) Shareholder meeting 37 slides Nov 12, 2026 American Society of Nephrology (ASN) Kidney Week 2026 Conference 14 slides Oct 23, 2026 EURetina 2026 Conference 19 slides Oct 2, 2026 Investor Presentation (September 2026) Investor deck 17 slides Sep 4, 2026 Neuro-Ophthalmology Society of Australia (NOSA) Annual Scientific Meeting 2026 Conference 16 slides Sep 3, 2026 2026 PMS Foundation Family Conference Conference 19 slides Jul 20, 2026 Corporate Update (May 2026) Corporate update 19 slides May 22, 2026 ARVO 2026 Conference 70 slides May 4, 2026 North American Neuro-Ophthalmology Society (NANOS) 2026 Conference Conference 16 slides Mar 24, 2026 Investor Presentation (February 2026) Investor deck 65 slides Feb 2, 2026
Show 50 decks Deck Kind Slides Date 44th annual JP Morgan Healthcare Conference 2026 Conference 40 slides Jan 13, 2026 Investor Presentation (January 2026) Investor deck 38 slides January 2026 Shareholder Meeting (November 2025) Shareholder meeting 10 slides Nov 18, 2025 Investor Presentation (October 2025) Investor deck 6 slides Oct 13, 2025 Technical Presentation (August 2025) Technical 16 slides Aug 29, 2025 Corporate Update (August 2025) Corporate update 25 slides Aug 1, 2025 Investor Presentation (May 2025) Investor deck 13 slides May 30, 2025 Foundation Fighting Blindness Retinal Therapeutics Innovation Summit 2025 Conference 25 slides May 2, 2025 Retinal Therapeutics Innovation Summit (May 2025) Conference 23 slides May 2, 2025 Investor Presentation (March 2025) Investor deck 21 slides Mar 28, 2025 Investor Presentation (February 2025) Investor deck 36 slides Feb 17, 2025 Investor Presentation (November 2024) Investor deck 12 slides Nov 28, 2024 Technical Presentation (November 2024) Technical 17 slides Nov 22, 2024 Shareholder Meeting (November 2024) Shareholder meeting 16 slides Nov 13, 2024 E&P Healthcare Conference 2024 Conference 9 slides Sep 26, 2024 Corporate Update (August 2024) Corporate update 23 slides Aug 30, 2024 Canaccord Genuity Growth Conference 2024 Conference 15 slides Aug 13, 2024 Bioshares Biotech Summit 2024 Conference 21 slides Jul 12, 2024 Corporate Update (May 2024) Corporate update 14 slides May 9, 2024 ARVO 2024 Conference 17 slides May 6, 2024 ARVO 2024 (Association for Research in Vision and Ophthalmology) Conference 20 slides May 6, 2024 Investor Presentation (March 2024) Investor deck 41 slides Mar 14, 2024 Euroz Hartleys Healthcare Conference 2024 Conference 12 slides Feb 6, 2024 Investor Presentation (February 2024) Investor deck 8 slides Feb 2, 2024 Shareholder Meeting (November 2023) Shareholder meeting 9 slides Nov 24, 2023 Investor Presentation (November 2023) Investor deck 21 slides Nov 17, 2023 Wilsons Drug & Device Conference 2023 Conference 13 slides Oct 26, 2023 Corporate Update (October 2023) Corporate update 17 slides Oct 5, 2023 Q3 2023 Earnings Presentation Earnings 9 slides Sep 27, 2023 E&P Healthcare Conference 2023 Conference 14 slides Sep 12, 2023 Investor Presentation (June 2023) Investor deck 19 slides Jun 16, 2023 BIO International Convention 2023 Conference 15 slides Jun 6, 2023 BIO 2023 Conference 31 slides Apr 19, 2023 Investor Presentation (February 2023) Investor deck 21 slides Feb 17, 2023 Investor Presentation (February 2023) Investor deck 37 slides Feb 3, 2023 Shareholder Meeting (November 2022) Shareholder meeting 17 slides Nov 23, 2022 Shareholder Meeting (November 2022) Shareholder meeting 17 slides Nov 23, 2022 Investor Presentation (May 2022) Investor deck 18 slides May 31, 2022 Q1 2022 Earnings Presentation Earnings 7 slides Mar 17, 2022 Shareholder Meeting (November 2021) Shareholder meeting 13 slides Nov 18, 2021
This page holds 50 of 102 decks. Open Decks
Open Decks
Financings Raise Date In US dollars Rights offering of new fully paid ordinary shares (retail entitlement offer) Closed: A$47M in the latest tranche · A$1.5 a share · E&P Capital Pty Ltd +2
Dealers: E&P Capital Pty Ltd (co-lead), Barrenjoey Markets Pty Limited (co-lead), Bloom Burton Securities Inc. (co-lead)
Use of proceeds: Advance PYC-003, PYC-002, VP-001 and PYC-001 drug candidates toward registrational or first-in-human trials, plus working capital, R&D and costs
Mar 4, 2026 Private placement of fully paid ordinary shares Closed: A$128M raised · A$1.5 a share · Bloom Burton Securities Inc.
Dealers: Bloom Burton Securities Inc. (lead)
Buyers: RA Capital Management; Perceptive Advisors; Driehaus Capital Management; MPM BioImpact; Rock Springs Capital; RTW Investments
Use of proceeds: Extend cash runway through CY2030 to deliver human safety and efficacy data for all four drug development programs
Feb 4, 2026 US$89.6M Rights offering of new fully paid ordinary shares Announced: about A$145.8M · A$1.25 a share · E&P Capital Pty Ltd +6
Dealers: E&P Capital Pty Ltd (co-lead), Barrenjoey Markets Pty Limited (co-lead), Custom Binders Pty Ltd, John Baird, Sami Zouad, Adrian Bonaddio, Dr Yang Sheng Yeo & Ms Esther Mei Yen Liaw as trustees for the Papy Family Trust
Buyers: Alan Tribe (intends to subscribe for New Shares with a value of A$35 million)
Insiders: Chairman Alan Tribe, holding 34% of shares, intends to subscribe for New Shares with a value of A$35 million
Use of proceeds: Advance blinding eye disease, polycystic kidney disease and Phelan-McDermid Syndrome drug candidates through human trials; working capital and offer costs
Feb 17, 2025 US$92.69M
Open Financings · Read by 6ix AI from the company's releases
Financials Annual, in AUD
Income statement Line FY2026 FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018 FY2017 Revenue 23.5M 22.1M 15.8M 16.0M 3.07M 2.40M 250 48.5K 2.76M Cost of revenue 1.20M 1.12M 1.07M 882.0K 839.5K 622.4K 547.1K 130.6K 81.3K 4.67M Gross profit -1.20M 23.5M 22.1M 14.9M 15.2M 2.45M 1.85M -130.6K -32.8K -1.91M Research and development 74.0M 70.1M 56.4M 35.1M 24.0M 14.0M 5.88M 4.51M 6.96M 4.67M Selling, general and administrative 6.69M 7.07M 4.51M 4.09M 6.30M 7.83M 3.82M 409.8K 1.16M 1.04M Operating income -82.7M -53.6M -38.9M -39.2M -30.2M -21.8M -9.70M -7.10M -9.77M -4.25M Depreciation and amortization 1.20M 1.12M 1.07M 882.0K 839.5K 622.4K 547.1K 130.6K 81.3K 55.3K EBITDA -81.5M -52.5M -37.8M -38.3M -29.4M -21.2M -9.15M -6.97M -9.69M -4.20M Interest expense 40.5K 62.2K 49.2K 27.3K 32.6K 38.8K 42.9K 118.2K 0 0 Income before tax -69.8M -51.0M -55.7M -39.2M -30.3M -21.7M -9.48M -6.98M -9.60M -4.18M Income tax -26.0M -23.5M -17.6M -15.8M -16.0M -3.07M -2.40M -2.90M -2.17M -2.22M Net income -43.3M -50.3M -37.7M -22.8M -13.9M -17.8M -6.82M -4.08M -7.43M -1.95M Earnings per share, basic -0.06 -0.10 -0.01 -0.01 -0.00 -0.01 -0.00 -0.00 -0.00 -0.00
Balance sheet Line FY2026 FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018 FY2017 Cash and equivalents 53.6M 153.1M 66.9M 15.6M 29.1M 18.4M 7.24M 1.66M 3.15M 9.94M Short-term investments 394.0M 0 33.1M 18.2M 4.52M Receivables 34.1M 24.1M 18.0M 16.3M 10.1M 185.6K 82.7K 10.8K 18.5K 192.2K Inventory -18.0M -42.7K -10.8K -192.2K Current assets 482.2M 177.5M 85.6M 31.9M 39.2M 51.8M 25.6M 6.22M 3.28M 10.1M Property, plant and equipment 1.90M 1.57M 1.04M 1.63M 1.49M 1.14M 482.9K 143.4K 216.1K Total assets 708.5M 183.3M 91.2M 37.2M 45.4M 57.9M 31.5M 6.70M 3.42M 10.3M Accounts payable 9.89M 8.75M 7.53M 4.92M 2.57M 2.35M 97.3K 193.7K 1.68M 1.45M Current liabilities 14.4M 12.3M 9.11M 8.41M 4.39M 3.30M 705.6K 401.9K 1.77M 1.49M Total debt 625.0K 1.02M 1.11M 315.5K 943.8K 730.4K 798.1K 798.1K Total liabilities 15.2M 13.3M 10.2M 8.72M 5.15M 4.02M 1.35M 401.9K 1.77M 1.49M Shareholders' equity 693.3M 169.6M 80.5M 27.7M 39.4M 53.0M 28.5M 6.30M 1.65M 8.86M Shares outstanding 732.6M 500.5M 3.94B 3.25B 3.22B 3.13B 2.80B 2.80B 2.22B 2.01B
Cash flow Line FY2026 FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018 FY2017 Cash from operations -44.5M -51.6M -38.6M -24.4M -21.8M -11.8M -5.75M -5.13M -6.71M -1.88M Capital spending -531.4K -975.4K -307.0K -491.1K -386.9K -591.0K -106.1K -457.5K -210.6K -4.54K Free cash flow -45.1M -52.5M -38.9M -24.9M -22.2M -12.4M -5.85M -5.58M -6.92M -1.89M Cash from investing -616.2M -975.4K -307.0K -477.1K 32.7M -15.5M -13.8M -4.98M -210.6K -3.46K Cash from financing 563.2M 138.7M 90.2M 11.4M -182.4K 38.6M 25.1M 8.62M 125.2K 4.75M Dividends paid -10.5M -36.3M -23.5M Share buybacks -36.6M -6.80M -1.57M -976.2K -976.2K -2.29M -1.62M -503.2K -9.82K -313.3K Change in cash -99.5M 86.2M 51.3M -13.5M 10.7M 11.2M 1.06M -1.49M -6.79M 2.87M
Open Financials
Filings Filing Date Type Filed with PKD Program - Enrolment Target Met Nov 12, 2026 Other filings ASX Results of Annual General Meeting Nov 11, 2026 Meeting outcome ASX 2026 Annual General Meeting Program and CEO Presentation Nov 11, 2026 Meeting notice ASX Notification regarding unquoted securities - PYC Nov 9, 2026 Other filings ASX Change of Director's Interest Notice Nov 5, 2026 Ownership change notice ASX Annual General Meeting - Conference Link Nov 4, 2026 Meeting notice ASX Change of Director's Interest Notice Nov 3, 2026 Ownership change notice ASX Change of Director's Interest Notice Oct 30, 2026 Ownership change notice ASX Exercise of Options and Cleansing Notice Oct 29, 2026 Financing ASX Application for quotation of securities - PYC Oct 29, 2026 Financing ASX
Show 200 filings Filing Date Type Filed with Quarterly Activities/Appendix 4C Cash Flow Report Oct 28, 2026 Quarterly report ASX Quarterly Activities/Appendix 4C Cash Flow Report Oct 28, 2026 Quarterly report ASX PKD Program - ASN Presentation Oct 22, 2026 Operations update ASX Exercise of Options and Cleansing Notice Oct 15, 2026 Financing ASX Notice of Annual General Meeting/Proxy Form Oct 11, 2026 Meeting notice ASX Application for quotation of securities - PYC Oct 7, 2026 Financing ASX Notification of cessation of securities - PYC Oct 7, 2026 Financing ASX PKD Program - Presentation of Data at ASN Conference Oct 6, 2026 Operations update ASX RP11 PROGRAM - PRESENTATION AT EURETINA 2026 Oct 1, 2026 Other filings ASX PKD - First Patient Dosed in OLE Study Sep 10, 2026 Operations update ASX S&P DJI Announces September 2026 Quarterly Rebalance Sep 4, 2026 Other filings ASX Investor Webinar Presentation Q3 2026 Sep 3, 2026 Other filings ASX ADOA Program - Data Presentation Sep 2, 2026 Other filings ASX Ceasing to be a substantial holder Sep 2, 2026 Ownership change notice ASX PKD - Presentation of Clinical Safety Data Aug 30, 2026 Other filings ASX 2026 Corporate Governance Statement Aug 28, 2026 Other filings ASX Appendix 4G Aug 28, 2026 Other filings ASX 2026 Annual Report to Shareholders Aug 28, 2026 Annual report ASX Appendix 4E Aug 28, 2026 Results ASX Notification regarding unquoted securities - PYC Aug 26, 2026 Other filings ASX Investor Webinar Aug 17, 2026 Other filings ASX Change of Director's Interest Notice Aug 13, 2026 Ownership change notice ASX Notification regarding unquoted securities - PYC Aug 13, 2026 Other filings ASX Quarterly Activities/Appendix 4C Cash Flow Report Jul 28, 2026 Quarterly report ASX PKD - Safety Committee Approves Dose Escalation Jul 21, 2026 Other filings ASX ADOA Program Update Jul 20, 2026 Other filings ASX PKD - Initiation of Multiple Dose Clinical Trial May 6, 2026 Other filings ASX Presentation of Ophthalmology Clinical Trial Data at ARVO May 3, 2026 Operations update ASX ADOA Program - SRC Approve Progression to Multi-Dose Study Apr 15, 2026 Other filings ASX Completion of Retail Entitlement Offer Mar 3, 2026 Financing ASX PKD Clinical Trial - Approval to Escalate Dosing Feb 26, 2026 Operations update ASX Half Yearly Report and Accounts Feb 23, 2026 Interim report ASX Retail Offer Booklet Feb 8, 2026 Offer document ASX Completion of Placement and Institutional Entitlement Offer Feb 3, 2026 Financing ASX PYC Raising up to $653m to Deliver Human Efficacy Data Feb 1, 2026 Financing ASX PYC Capital Raising Presentation Feb 1, 2026 Offer document ASX Trading Halt Feb 1, 2026 Trading halt or suspension ASX Quarterly Activities/Appendix 4C Cash Flow Report Jan 22, 2026 Quarterly report ASX PKD Clinical Trial - Safety Outcomes in Part A Dec 18, 2025 Operations update ASX Sustained Vision Improvement in RP11 Patients Nov 13, 2025 Operations update ASX ADOA Program Initiation of Global Repeat Dose Study Oct 20, 2025 Other filings ASX PMS Program Data Supports Progression to Human Trials Oct 12, 2025 Other filings ASX ADOA Program Progressing to Multiple Dose Study Oct 8, 2025 Other filings ASX Board and Management Changes Sep 21, 2025 Management or board change ASX Correction to Trading Halt Request Sep 19, 2025 Trading halt or suspension ASX Change of Managing Director Sep 16, 2025 Management or board change ASX ADOA Program - Presentation of Clinical Data at NOSA 2025 Sep 4, 2025 Other filings ASX PKD Program - Presentation of Safety Data at ANZSN Aug 28, 2025 Other filings ASX Appendix 4E Aug 28, 2025 Results ASX Approval to Escalate Dosing in Kidney Disease Clinical Trial Aug 7, 2025 Operations update ASX Approval to Progress Kidney Disease Trial to Next Stage Jul 6, 2025 Operations update ASX Fourth Drug Program Progressing to Human Trials Jun 26, 2025 Other filings ASX FDA Alignment on Registrational Trial Design RP11 Program Jun 22, 2025 Other filings ASX SRC Approves Dose Escalation in ADOA Clinical Trial Jun 10, 2025 Other filings ASX Approval to Escalate Dosing in Kidney Disease Trial May 25, 2025 Operations update ASX Presentation of Clinical Proof of Concept in Lead Program Apr 27, 2025 Other filings ASX Completion of Entitlement Offer Apr 16, 2025 Financing ASX First Subject Dosed in PKD Clinical Trial Apr 9, 2025 Other filings ASX Placement of Shortfall Apr 9, 2025 Financing ASX Retail Entitlement Offer Booklet Feb 24, 2025 Offer document ASX Completion of Institutional Entitlement Offer Feb 18, 2025 Financing ASX PYC Equity Raising Presentation Feb 16, 2025 Offer document ASX PYC Equity Raising to Raise up to $146 Million Feb 16, 2025 Financing ASX Approval to Commence Human Trials in Kidney Program Feb 9, 2025 Other filings ASX ADOA Safety Review Committee Approves Dose Escalation Jan 30, 2025 Operations update ASX US FDA Grants Rare Pediatric Disease Designation to VP-001 Jan 19, 2025 Other filings ASX PYC Nominates Fourth Clinical Drug Candidate in PMS Program Dec 15, 2024 Other filings ASX PYC to Progress Kidney Drug Candidate Into Human Trials Nov 26, 2024 Other filings ASX Consolidation/Split - PYC Nov 11, 2024 Other filings ASX RP11 SRC Approves Dose Escalation to Final Patient Cohort Nov 4, 2024 Other filings ASX First ADOA Patient Dosed in Clinical Trial Oct 31, 2024 Other filings ASX Interim Update on Progress in RP11 Repeat Dose Trials Oct 21, 2024 Interim report ASX US FDA Grants Orphan Drug Designation to PYC Drug Candidate Oct 20, 2024 Other filings ASX Notice of Annual General Meeting/Proxy Form Oct 14, 2024 Meeting notice ASX FDA Grants Rare Pediatric Disease Designation to PYC-001 Aug 29, 2024 Other filings ASX Appendix 4E and Audited Financial Statements Aug 29, 2024 Results ASX PYC to Start Human Trials in Second Blinding Eye Disease Aug 14, 2024 Other filings ASX Visual Improvement in Multiple RP11 Patients Aug 11, 2024 Other filings ASX RP11 Clinical Trial Update - Amended Aug 5, 2024 Other filings ASX RP11 Clinical Trial Update Aug 4, 2024 Operations update ASX Extension of RP11 Single Dose Study Into Multiple Dose Study Jul 22, 2024 Operations update ASX Initial Dosing Completed in Cohort 1 of RP11 MAD Study Jul 16, 2024 Operations update ASX Commencement of RP11 Multiple Dose Trial Jul 9, 2024 Operations update ASX RP11 Drug Candidate Safe and Well Tolerated Jun 30, 2024 Other filings ASX PMS Drug Candidate Effective In Human Brain Cells Jun 6, 2024 Operations update ASX RP11 Clinical Trial Dosing Completed in Cohort 4 May 15, 2024 Operations update ASX Successful GLP Tox Studies in Second Blinding Eye Disease May 13, 2024 Operations update ASX Presentation of RP11 Clinical Trial Data at ARVO Conference May 5, 2024 Other filings ASX RP11 Drug Candidate Progressing to Mid-Stage Human Trials Apr 28, 2024 Other filings ASX Kidney Disease Drug Candidate Progressing to Human Trials Apr 21, 2024 Operations update ASX $74.6 Million Extension of Cash Runway Apr 10, 2024 Financing ASX PYC Equity Raising to Raise up to $74.6 Million Mar 13, 2024 Financing ASX RP11 Clinical Trial - Dosing Completed in Cohort 3 Feb 27, 2024 Operations update ASX Receipt of $4.5m Collaboration Fee Feb 16, 2024 Other filings ASX AI Driven Drug Discovery Collaboration with Google Cloud Jan 1, 2024 Operations update ASX RP11 Clinical Trial Progressing To High Dose Cohort Dec 17, 2023 Other filings ASX Response to Price Query Nov 30, 2023 Explanation request ASX Supplementary Information Nov 16, 2023 Other filings ASX New Drug For Major Kidney Disease Effective In Human Models Nov 12, 2023 Other filings ASX PYC and FDA Align On Clinical Trial Pathway in ADOA Nov 5, 2023 Operations update ASX RP11 Clinical Trial Dosing Completed In Patient Cohort 2 Nov 2, 2023 Operations update ASX PYC-001 Effective In Both NHPs and Patient-Derived Models Oct 3, 2023 Other filings ASX Safety Review Committee Approves Dose Escalation Sep 21, 2023 Other filings ASX RP11 Clinical Trial Dosing Completed In Patient Cohort 1 Aug 17, 2023 Other filings ASX PYC Increases Ownership of VP-001 Program Aug 9, 2023 Other filings ASX PYC Receives FDA Fast Track Designation Aug 1, 2023 Other filings ASX Successful Toxicology Results Pave Way for Phase 2 Trial Jul 17, 2023 Other filings ASX FIRST PATIENT DOSED IN EYE DISEASE CLINICAL TRIAL Jun 29, 2023 Other filings ASX Placement Supporting Document May 11, 2023 Financing ASX Successful Completion of $30m Placement May 10, 2023 Financing ASX Commencement of First Clinical Study in RP11 Apr 25, 2023 Other filings ASX Second Drug Program Progressing to Human Trials Apr 3, 2023 Other filings ASX FDA Clears PYC to Commence First Human Trials in RP11 Mar 5, 2023 Other filings ASX VP-001 IND Lodgement Feb 1, 2023 Other filings ASX Successful Toxicology Studies Pave Way for Human Trials Nov 6, 2022 Other filings ASX Central Nervous System Drug Program Added to PYC Pipeline Sep 26, 2022 Other filings ASX Preliminary Final Report Aug 30, 2022 Results ASX PYC Increases Shareholding in Vision Pharma Feb 16, 2022 Other filings ASX Quarterly Activities and Appendix 4C Cash Flow Report Jan 26, 2022 Quarterly report ASX Successful Completion of Key Translational Milestone Nov 15, 2021 Other filings ASX Retina Target Engagement Confirmed in Large Eye Sep 29, 2021 Other filings ASX Second Drug Program Progressing Towards Human Trials Jun 8, 2021 Other filings ASX March 2021 Quarterly Report and Cashflow Apr 29, 2021 Quarterly report ASX Lead Investigational Drug Demonstrates Key Improvement Mar 1, 2021 Legal or regulatory action ASX Half Year Accounts and Appendix 4D Feb 26, 2021 Interim report ASX Progress US Clinical Stage Company and Corporate Objectives Feb 21, 2021 Other filings ASX Quarterly Activities Report and Appendix 4C Jan 29, 2021 Quarterly report ASX Visual Evidence of Lead Drugs Efficacy Dec 15, 2020 Other filings ASX Review of Activities and Appendix 4C Oct 26, 2020 Quarterly report ASX Successful Institutional Entitlement Offer and Placement Oct 21, 2020 Financing ASX PYC Business and Equity Raising Presentation Oct 19, 2020 Other filings ASX PYC Equity Raising to Raise up to $55 Million Oct 19, 2020 Other filings ASX New Drug for Substantial Unmet Need Added to Pipeline Oct 11, 2020 Other filings ASX PYCs Lead Drug Effective in Patient Derived Models Tested Oct 6, 2020 Other filings ASX Second Potential Blockbuster Drug Added to PYCs Pipeline Oct 4, 2020 Other filings ASX Creation of Novel Gene Therapy Delivery Technology Sep 7, 2020 Other filings ASX Appendix 4E Preliminary Final Report Aug 31, 2020 Results ASX Executive re-structure across global operations Aug 19, 2020 Other filings ASX Shareholder Update - Forward View 2020 Milestones Aug 4, 2020 Other filings ASX June 2020 Quarterly Activity Report and Cashflow Jul 30, 2020 Other filings ASX Successful Dose Response & Toxicity Studies in Lead Program Jul 21, 2020 Other filings ASX S&P DJI Announces June 2020 Quarterly Rebalance Jun 11, 2020 Other filings ASX March 2020 Quarterly Activities and Cash Flow Report Apr 29, 2020 Quarterly report ASX Successful Efficacy Result on Path to First in Human Studies Mar 31, 2020 Other filings ASX Investor Presentation - February 2020 Feb 23, 2020 Other filings ASX CEO Appointment and Establishment of US Office Feb 12, 2020 Other filings ASX Expansion Of Drug Development Pipeline Feb 2, 2020 Other filings ASX Appendix 4C - quarterly Jan 31, 2020 Quarterly report ASX Quarterly Shareholder Update Jan 5, 2020 Other filings ASX Drug Delivery Greater Than 100% More Effective In Animals Dec 1, 2019 Other filings ASX Conclusion of Genentech Antimicrobial Collaboration Nov 14, 2019 Other filings ASX Retail Offer Document Nov 3, 2019 Offer document ASX PYCs Institutional Entitlement Offer Closes Nov 3, 2019 Financing ASX Entitlement Offer - Investor Presentation Oct 31, 2019 Financing ASX $26.8m Fully Underwritten Accelerated Entitlement Offer Oct 30, 2019 Financing ASX Sept 2019 Quarterly Shareholder Update and Appendix 4C Oct 30, 2019 Quarterly report ASX Successful Major Milestone - Human Retina in a Dish Models Oct 8, 2019 Other filings ASX Strategic Partnership and Lead Program Oct 1, 2019 Other filings ASX Successful Time-Course Studies in Animals Sep 25, 2019 Other filings ASX Successful Competitive Drug Evaluation in Animals Sep 2, 2019 Other filings ASX Successful Time - Course Studies in Animals Aug 22, 2019 Other filings ASX Response to ASX Aware Query Aug 7, 2019 Explanation request ASX Phylogicas Technology is Effective in Human Cells Aug 6, 2019 Other filings ASX Company Presentation - July 2019 Jul 23, 2019 Other filings ASX Operational Update and Appendix 4C Jul 23, 2019 Quarterly report ASX Animal Models - 400% Outperformance of Gold Standard Jul 22, 2019 Other filings ASX Break Through Animal Model Results Jun 26, 2019 Other filings ASX March 2019 Quarterly Operational Update and App4C Apr 29, 2019 Other filings ASX Collaboration Agreement - siRNA delivery Mar 13, 2019 Other filings ASX Flagship Program - Successful Animal Models Mar 11, 2019 Other filings ASX First Competitive Read Out - Peptide Vaccine Feb 8, 2019 Other filings ASX Dec 2018 Operational Update and App4C Jan 31, 2019 Other filings ASX CEO letter and Operational Update Jan 16, 2019 Other filings ASX In Vivo Success - peptide vaccine (Amended Graphics) Dec 6, 2018 Other filings ASX In vivo success - peptide vaccine in Herpes Simplex Virus Dec 6, 2018 Other filings ASX Successful Delivery of CRIPR/Cas9 into Cells ex vivo Dec 3, 2018 Other filings ASX FNA Presentation Nov 22, 2018 Other filings ASX AGM Company Presentation Nov 16, 2018 Other filings ASX Sept 2018 Quarterly Operations Update and App4C Oct 31, 2018 Operations update ASX Fourfold Delivery Improvement in a New Lead Candidate Oct 29, 2018 Other filings ASX R&D Tax Incentive Refund Oct 8, 2018 Other filings ASX Reinstatement to Official Quotation Sep 11, 2018 Trading halt or suspension ASX Phylogica Recapitalisation Sep 11, 2018 Other filings ASX Suspension from Official Quotation Sep 10, 2018 Trading halt or suspension ASX Update on Capital Raising Sep 10, 2018 Financing ASX June 2018 Quarterly Operational Update and App4C Jul 31, 2018 Other filings ASX Achievement of Major Milestone - In vivo Cre Delivery Jul 30, 2018 Other filings ASX Successful In-vivo Results Peptide Vaccine T-Cell Expansion Jul 26, 2018 Other filings ASX CEO Update Jul 8, 2018 Other filings ASX March 2018 Operational Update and Cashflow Apr 30, 2018 Other filings ASX
This page holds 200 of 284 filings. Open Filings
Open Filings
Cap table Built by 6ix from PYC Therapeutics Limited’s releases · as of Mar 4, 2026
Common shares 984,210,447
Fully diluted 984,210,447 Fully diluted Line Shares Common shares 984,210,447
Share count over time Count Shares Nov 22, 2026 984,210,447
Open Cap table
Shareholders Funds Holder Shares Value As of iShares MSCI EAFE Small-Cap ETF 1.86M US$2.22M Jul 31, 2026 Vanguard Total International Stock Index Fund 1.23M US$1.46M Jul 31, 2026 The Asia Pacific Small Company Series 379K US$453K Jul 31, 2026 iShares Core MSCI EAFE ETF 333K US$398K Jul 31, 2026 College Retirement Equities Fund - Total Global Stock Account 323K US$377K Jun 30, 2026 Vanguard Ftse All-World Ex-Us Small-Cap Index Fund 315K US$377K Jul 31, 2026 iShares Core MSCI Total International Stock ETF 188K US$224K Jul 31, 2026 Fidelity SAI International Small Cap Index Fund 151K US$179K Jul 31, 2026 iShares Core MSCI Pacific ETF 136K US$163K Jul 31, 2026 Vanguard Pacific Stock Index Fund 88,701 US$106K Jul 31, 2026
All 13 holders Insider trades Trade Trade Shares Price Value Date Peter Coleman Director
Buy 105,820 AUD 1.91 AUD 202K Oct 30, 2026
Open Shareholders
People 6ix reads each seat by machine from the page it links to, and can misread one.
Person Seat Candice Junge Chief Clinical Development Officer · Since at least Nov 5, 2026 Garrett Bray Chief Operating Officer · Since at least Nov 5, 2026 Ian Constable Non-Executive Director · Since at least Nov 5, 2026 Janya Grainok Chief Scientific Officer · Since at least Nov 5, 2026 Jonathan Riley General Counsel · Since at least Nov 5, 2026 Paula Cunningham Chief Development Officer · Since at least Nov 5, 2026 Peter Coleman Independent Non-Executive Chair · Since at least Nov 5, 2026 Rohan Hockings Executive Director & Chief Executive Officer · Since at least Nov 5, 2026 Thomas Ulmer Chief Financial Officer · Since at least Nov 5, 2026
Open People
Log in to ask 6ix AI your own questions about PYC Therapeutics Limited.